Drug Profile
Human papilloma virus e6/e7 oncoproteins specific TCR T-cell therapy - Juno Therapeutics
Alternative Names: HPV e6/e7 oncoprotein TCR T cell therapy - Juno Therapeutics; HPV oncoproteins specific TCR T-cell therapy - Juno Therapeutics; TCR cell therapy targeting HPV oncoproteins e6/e7- Juno TherapeuticsLatest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator Juno Therapeutics
- Class Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer